File S1 - Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012

Supporting Information Table S1, Baseline characteristics and antiretroviral therapy use among the study population. Legend: amedian (IQR); bnumber (%); cmedian (95%CI); *C (n = 3), G (n = 2), A1 (n = 1), F1 (n = 1); **recombinant subtypes: CRF01_AE (n = 1), CRF02_AG (n = 10), CRF12_BF (n = 1), CRF13_cpx (n = 1); #3TC/ddI+d4T+NFV (n = 23; 48.9%); ##AZT/ABV +3TC+KLT (n = 16; 53.3%); ∧d4T+ddI+EFV (n = 7; 29.2%); ∧∧AZT +3TC+ABV+NVP (n = 2; 100%); ∧∧∧AZT +3TC+ddI (n = 1; 100%). CRF, circulating recombinant form; HAART, highly active antiretroviral therapy; MTCT, mother-to-child transmission; PMTCT, antiretroviral prophylaxis of HIV mother-to-child transmission; CMV, cytomegalovirus; HBV, hepatitis B virus; NRTI, nonnucleoside/nucleotide reverse-transcriptase inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor. Supporting Information Table S2, Characteristics of included and not included patients. Legend: $Fisher's exact test (2-tailed); $$Mann-Whitney U test (2-tailed). Supporting Information Table S3, Analysis of the cause of discontinuation of first-line HAART according to the type of regimen. Legend: NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; *the underlying cause of death was dideoxynucleoside-induced severe lactic acidosis. Supporting Information Figure S1, Evolution of the percentage of the most frequent antiretroviral drug over time (A) and evolution of viral load (VL), Í8 and Í4 over time (B). Legend: Mean of log10 VL (copies/mL), CD8+ T-cell percentage and CD4+ T-cell percentage; bars represent 2 s.e.m. EFV, efavirenz; KLT, kaletra; NFV, nelfinavir. (DOCX)